These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 38022586)
21. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. AIDS Vaccine Evaluation Group 022 Protocol Team J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981 [TBL] [Abstract][Full Text] [Related]
22. Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. Kim AS; Leaman DP; Zwick MB PLoS Pathog; 2014 Jul; 10(7):e1004271. PubMed ID: 25058619 [TBL] [Abstract][Full Text] [Related]
23. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. Pollara J; Bonsignori M; Moody MA; Liu P; Alam SM; Hwang KK; Gurley TC; Kozink DM; Armand LC; Marshall DJ; Whitesides JF; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; O'Connell RJ; Kim JH; Michael NL; Montefiori DC; Tomaras GD; Liao HX; Haynes BF; Ferrari G J Virol; 2014 Jul; 88(14):7715-26. PubMed ID: 24807721 [TBL] [Abstract][Full Text] [Related]
24. Corrigendum: Complement-Opsonized HIV Modulates Pathways Involved in Infection of Cervical Mucosal Tissues: A Transcriptomic and Proteomic Study. Svanberg C; Ellegård R; Crisci E; Khalid M; Wodlin NB; Svenvik M; Nyström S; Birse K; Burgener A; Shankar EM; Larsson M Front Immunol; 2021; 12():730130. PubMed ID: 34305955 [TBL] [Abstract][Full Text] [Related]
25. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope. Kilgore KM; Murphy MK; Burton SL; Wetzel KS; Smith SA; Xiao P; Reddy S; Francella N; Sodora DL; Silvestri G; Cole KS; Villinger F; Robinson JE; Pulendran B; Hunter E; Collman RG; Amara RR; Derdeyn CA J Virol; 2015 Aug; 89(16):8130-51. PubMed ID: 26018167 [TBL] [Abstract][Full Text] [Related]
26. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681 [TBL] [Abstract][Full Text] [Related]
27. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. Bar KJ; Tsao CY; Iyer SS; Decker JM; Yang Y; Bonsignori M; Chen X; Hwang KK; Montefiori DC; Liao HX; Hraber P; Fischer W; Li H; Wang S; Sterrett S; Keele BF; Ganusov VV; Perelson AS; Korber BT; Georgiev I; McLellan JS; Pavlicek JW; Gao F; Haynes BF; Hahn BH; Kwong PD; Shaw GM PLoS Pathog; 2012; 8(5):e1002721. PubMed ID: 22693447 [TBL] [Abstract][Full Text] [Related]
28. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y J Virol; 2017 May; 91(9):. PubMed ID: 28202751 [TBL] [Abstract][Full Text] [Related]
29. Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. Devasundaram S; Rosati M; Valentin A; Weiss S; Itri V; Trinh HV; Bear J; Chowdhury B; LaBranche CC; Montefiori D; Ferrari G; Rao M; Kong XP; Zolla-Pazner S; Pavlakis GN; Felber BK J Virol; 2020 Dec; 95(2):. PubMed ID: 33087466 [TBL] [Abstract][Full Text] [Related]
30. Corrigendum: Brief research report: impact of vaccination on antibody responses and mortality from severe COVID-19. Adhikari B; Bednash JS; Horowitz JC; Rubinstein MP; Vlasova AN Front Immunol; 2024; 15():1384209. PubMed ID: 38482012 [TBL] [Abstract][Full Text] [Related]
31. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes. Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444 [TBL] [Abstract][Full Text] [Related]
33. Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation. Guzzo C; Zhang P; Liu Q; Kwon AL; Uddin F; Wells AI; Schmeisser H; Cimbro R; Huang J; Doria-Rose N; Schmidt SD; Dolan MA; Connors M; Mascola JR; Lusso P mBio; 2018 Dec; 9(6):. PubMed ID: 30538178 [TBL] [Abstract][Full Text] [Related]
34. Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States. Johnson J; Zhai Y; Salimi H; Espy N; Eichelberger N; DeLeon O; O'Malley Y; Courter J; Smith AB; Madani N; Sodroski J; Haim H J Virol; 2017 Aug; 91(15):. PubMed ID: 28490588 [TBL] [Abstract][Full Text] [Related]
35. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines. Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158 [TBL] [Abstract][Full Text] [Related]
38. Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. Phillips B; Fouda GG; Eudailey J; Pollara J; Curtis AD; Kunz E; Dennis M; Shen X; Bay C; Hudgens M; Pickup D; Alam SM; Ardeshir A; Kozlowski PA; Van Rompay KKA; Ferrari G; Moody MA; Permar S; De Paris K Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28814388 [TBL] [Abstract][Full Text] [Related]
39. Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions. Schriek AI; van Haaren MM; Poniman M; Dekkers G; Bentlage AEH; Grobben M; Vidarsson G; Sanders RW; Verrips T; Geijtenbeek TBH; Heukers R; Kootstra NA; de Taeye SW; van Gils MJ Front Immunol; 2022; 13():1091668. PubMed ID: 36483568 [TBL] [Abstract][Full Text] [Related]